ID: ALA3234923

Max Phase: Preclinical

Molecular Formula: C20H19NO3

Molecular Weight: 321.38

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(-c2cccc(-c3ccc(OC)cc3OC)n2)cc1

Standard InChI:  InChI=1S/C20H19NO3/c1-22-15-9-7-14(8-10-15)18-5-4-6-19(21-18)17-12-11-16(23-2)13-20(17)24-3/h4-13H,1-3H3

Standard InChI Key:  XALBYFGOYHPROL-UHFFFAOYSA-N

Associated Targets(Human)

MDA-MB-231 73002 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A549 127892 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HeLa 62764 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Tubulin 5180 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Tubulin 2175 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Chorioallantoic membrane 375 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 321.38Molecular Weight (Monoisotopic): 321.1365AlogP: 4.44#Rotatable Bonds: 5
Polar Surface Area: 40.58Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 3.23CX LogP: 4.35CX LogD: 4.35
Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.70Np Likeness Score: -0.54

References

1. Zheng S, Zhong Q, Mottamal M, Zhang Q, Zhang C, Lemelle E, McFerrin H, Wang G..  (2014)  Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents.,  57  (8): [PMID:24669888] [10.1021/jm500002k]

Source